acth-(4-7)--pro-gly-pro- and Parkinsonian-Disorders

acth-(4-7)--pro-gly-pro- has been researched along with Parkinsonian-Disorders* in 2 studies

Other Studies

2 other study(ies) available for acth-(4-7)--pro-gly-pro- and Parkinsonian-Disorders

ArticleYear
Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism.
    Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2017, Volume: 474, Issue:1

    Parkinson's disease (PD) is the second most common severe neurodegenerative disorder that is characterized by progressive degeneration of dopaminergic neurons (DA neurons) in the substantia nigra pars compacta (SNpc) region of the brain. In the present study, we investigated the effects of the synthetic regulatory peptides Semax (analog of an ACTH 4-10 fragment (ACTH4-10)) and Selank (analog of immunomodulatory taftsin) on behavior of rats with 6-hydroxidopamine (6-OHDA) induced PD-like parkinsonism. It was showed that both peptides did not affect motor activity of rats in elevated cross shaped maze and passive defensive behavior of the animals. At the same time, Selank decreased level of anxiety of rats with toxic damage of DA neurons in elevated cross shaped maze. Previously such effects of Selank were revealed in healthy rodents (rats and mice) with different models of psycho-emotional stress. Therefore, toxic damage of substantia nigra does not affect the response of the rat organism on this peptide.

    Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Disease Models, Animal; Dopaminergic Neurons; Male; Oligopeptides; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Pars Compacta; Peptide Fragments; Rats

2017
The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system.
    Neuroscience and behavioral physiology, 2004, Volume: 34, Issue:4

    This report describes studies cf the effects of the ACTH(4-10) analog Semax (MEHFPGP) on the behavior of white rats with lesions to the brain dopaminergic system induced by the neurotoxin MPTP. Neurotoxin was given as single i.p. doses of 25 mg/kg. Neurotoxin injections were shown to decrease movement activity and increase anxiety in the animals. Daily intranasal administration of Semax at a dose of 0.2 mg/kg decreased the severity of MPTP-induced behavioral disturbances. The protective activity of Semax in MPTP-induced lesions of the brain dopaminergic system may be associated with both its modulating effect on the dopaminergic system and the neurotrophic action of the peptide.

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenocorticotropic Hormone; Animals; Anxiety; Disease Models, Animal; Dopamine; Exploratory Behavior; Male; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Peptide Fragments; Rats; Statistics as Topic; Statistics, Nonparametric; Substantia Nigra

2004